Richard T Gray1, Jo Watson2, Aaron J Cogle2, Don E Smith3, Jennifer F Hoy4, Lisa A Bastian5, Robert Finlayson6, Fraser M Drummond7, Bill Whittaker2, Matthew G Law1, Kathy Petoumenos1. 1. The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia. 2. National Association of People with HIV Australia (NAPWHA), Sydney, NSW 2042, Australia. 3. Albion Centre, Sydney, NSW 2010, Australia. 4. Department of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne Vic. 3181, Australia. 5. Western Australian Department of Health, Perth, WA 6004, Australia. 6. Taylor Square Private Clinic, Taylor Square, Sydney, NSW 2010, Australia. 7. ViiV Healthcare, Abbotsford, VIC 3067, Australia.
Abstract
Background The aim of this study is to estimate the reduction in new HIV infections and resultant cost outcomes of providing antiretroviral treatment (ART) through Australia's 'universal access' health scheme to all temporary residents with HIV infection living legally in Australia, but currently deemed ineligible to access subsidised ART via this scheme. METHODS: A mathematical model to estimate the number of new HIV infections averted and the associated lifetime costs over 5 years if all HIV-positive temporary residents in Australia had access to ART and subsidised medical care was developed. Input data came from a cohort of 180 HIV-positive temporary residents living in Australia who are receiving free ART donated by pharmaceutical companies for up to 4 years. RESULTS: Expanding ART access to an estimated total 450 HIV+ temporary residents in Australia for 5 years could avert 80 new infections. The model estimated the total median discounted (5%) cost for ART and associated care to be A$36million, while the total savings in lifetime-discounted costs for the new infections averted was A$22million. CONCLUSIONS: It is estimated that expanded access to ART for all HIV-positive temporary residents in Australia will substantially reduce HIV transmission to their sexual partners at little additional cost. In the context of Australia's National HIV strategy and Australia's endorsement of global goals to provide universal access to ART for all people with HIV, this is an important measure to remove inequities in the provision of HIV-related treatment and care.
Background The aim of this study is to estimate the reduction in new HIV infections and resultant cost outcomes of providing antiretroviral treatment (ART) through Australia's 'universal access' health scheme to all temporary residents with HIV infection living legally in Australia, but currently deemed ineligible to access subsidised ART via this scheme. METHODS: A mathematical model to estimate the number of new HIV infections averted and the associated lifetime costs over 5 years if all HIV-positive temporary residents in Australia had access to ART and subsidised medical care was developed. Input data came from a cohort of 180 HIV-positive temporary residents living in Australia who are receiving free ART donated by pharmaceutical companies for up to 4 years. RESULTS: Expanding ART access to an estimated total 450 HIV+ temporary residents in Australia for 5 years could avert 80 new infections. The model estimated the total median discounted (5%) cost for ART and associated care to be A$36million, while the total savings in lifetime-discounted costs for the new infections averted was A$22million. CONCLUSIONS: It is estimated that expanded access to ART for all HIV-positive temporary residents in Australia will substantially reduce HIV transmission to their sexual partners at little additional cost. In the context of Australia's National HIV strategy and Australia's endorsement of global goals to provide universal access to ART for all people with HIV, this is an important measure to remove inequities in the provision of HIV-related treatment and care.
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Margaret May; Andrew Boulle; Sam Phiri; Eugene Messou; Landon Myer; Robin Wood; Olivia Keiser; Jonathan A C Sterne; Francois Dabis; Matthias Egger Journal: Lancet Date: 2010-07-15 Impact factor: 79.321
Authors: Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Alison J Rodger; Valentina Cambiano; Tina Bruun; Pietro Vernazza; Simon Collins; Jan van Lunzen; Giulio Maria Corbelli; Vicente Estrada; Anna Maria Geretti; Apostolos Beloukas; David Asboe; Pompeyo Viciana; Félix Gutiérrez; Bonaventura Clotet; Christian Pradier; Jan Gerstoft; Rainer Weber; Katarina Westling; Gilles Wandeler; Jan M Prins; Armin Rieger; Marcel Stoeckle; Tim Kümmerle; Teresa Bini; Adriana Ammassari; Richard Gilson; Ivanka Krznaric; Matti Ristola; Robert Zangerle; Pia Handberg; Antonio Antela; Sris Allan; Andrew N Phillips; Jens Lundgren Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Kathy Petoumenos; Jo Watson; Bill Whittaker; Jennifer Hoy; Don Smith; Lisa Bastian; Robert Finlayson; Andrew Sloane; Stephen T Wright; Hamish McManus; Matthew G Law Journal: J Int AIDS Soc Date: 2015-02-12 Impact factor: 5.396
Authors: Constantin Theodore Yiannoutsos; Leigh Francis Johnson; Andrew Boulle; Beverly Sue Musick; Thomas Gsponer; Eric Balestre; Matthew Law; Bryan E Shepherd; Matthias Egger Journal: Sex Transm Infect Date: 2012-12 Impact factor: 3.519
Authors: Ye Zhang; Virginia Wiseman; Tanya L Applegate; Richard De Abreu Lourenco; Deborah J Street; Kirsty Smith; Muhammad S Jamil; Fern Terris-Prestholt; Christopher K Fairley; Anna McNulty; Adam Hynes; Karl Johnson; Eric P F Chow; Benjamin R Bavinton; Andrew Grulich; Mark Stoove; Martin Holt; John Kaldor; Rebecca Guy; Jason J Ong Journal: Front Med (Lausanne) Date: 2022-04-19
Authors: Phillip Keen; Richard T Gray; Barbara Telfer; Rebecca Guy; Heather-Marie Schmidt; Bill Whittaker; Jo Holden; Martin Holt; Anthony Kelleher; David Wilson; Denton Callander; David A Cooper; Garrett Prestage; Christine Selvey; Andrew E Grulich Journal: J Int AIDS Soc Date: 2018-04 Impact factor: 5.396
Authors: Tafireyi Marukutira; Richard T Gray; Caitlin Douglass; Carol El-Hayek; Clarissa Moreira; Jason Asselin; Basil Donovan; Tobias Vickers; Tim Spelman; Suzanne Crowe; Rebecca Guy; Mark Stoove; Margaret Hellard Journal: PLoS Med Date: 2020-03-10 Impact factor: 11.069